Phase 3
N=1,008
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
Platelet Inhibition · Coronary Stent Implantation
Bottom Line
View on ClinicalTrials.gov: NCT01515345 ↗Enrolled (actual)
1,008
Serious AEs
4.4%
Results posted
May 2013
Primary outcome: Primary: Definite Stent Thrombosis — 1; 0 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- prasugrel or ticagrelor (Drug); Clopidogrel (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Kaiser Franz Josef Hospital
- Primary completion
- Jan 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Definite Stent Thrombosis |
1; 0 | — |
| PRIMARY Any Bleeding Event |
17; 9 | — |
| SECONDARY Probable Stent Thrombosis |
2; 0 | — |
Summary
The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer).
Eligibility Criteria
Inclusion Criteria
- all consecutive PCI patients with stent implantation of our institution
Exclusion Criteria
- pregnancy
Data sourced from ClinicalTrials.gov (NCT01515345). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.